We are live on !
Find out more
Pfizer Portfolio holdings
AUM
$170M
Turnover
5.56%
1-Year Est. Return
191.09%
This Fund
S&P 500
This Quarter Est. Return
-25.45%
1 Year Est. Return
+191.09%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$501M
AUM Growth
-$2.09B
(-81%)
Cap. Flow
-$1.9B
Cap. Flow % of AUM
Cap. Flow %
-378.75%
Top 10 Holdings %
Top 10 Hldgs %
96.83%
Holding
23
New
–
Increased
1
Reduced
–
Closed
2
Avg Time Held
0.3
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NextCure
NXTC
|
+$318K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haleon
HLN
|
+$1.88B |
| 2 |
Akero Therapeutics
AKRO
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
BioNTech
BNTX
$22.1B
| $333M | 66.51% |
3,658,361
| – | – |
2024 Q4
1 quarter
|
|
2
Allogene Therapeutics
ALLO
$432M
| $32.2M | 6.42% |
22,032,040
| – | – |
2024 Q4
1 quarter
|
|
3
Oric Pharmaceuticals
ORIC
$1.37B
| $30M | 5.99% |
5,376,344
| – | – |
2024 Q4
1 quarter
|
|
4
Arvinas
ARVN
$477M
| $24.3M | 4.85% |
3,457,815
| – | – |
2024 Q4
1 quarter
|
|
5
DELISTED
Tourmaline Bio
TRML
| $19.4M | 3.86% |
1,272,214
| – | – |
2024 Q4
1 quarter
|
|
6
Wave Life Sciences
WVE
$627M
| $15.2M | 3.02% |
1,875,000
| – | – |
2024 Q4
1 quarter
|
|
7
Biohaven
BHVN
$2.1B
| $12.2M | 2.43% |
505,645
| – | – |
2024 Q4
1 quarter
|
|
8
Cardiff Oncology
CRDF
$70.6M
| $7.57M | 1.51% |
2,411,575
| – | – |
2024 Q4
1 quarter
|
|
9
Pyxis Oncology
PYXS
$140M
| $6.89M | 1.38% |
7,032,770
| – | – |
2024 Q4
1 quarter
|
|
10
Caribou Biosciences
CRBU
$57.1M
| $4.28M | 0.86% |
4,690,431
| – | – |
2024 Q4
1 quarter
|
|
11
Zura Bio
ZURA
$322M
| $3.83M | 0.77% |
2,970,022
| – | – |
2024 Q4
1 quarter
|
|
12
Celcuity
CELC
$3.19B
| $3.53M | 0.71% |
349,406
| – | – |
2024 Q4
1 quarter
|
|
13
DELISTED
ESSA Pharma
EPIX
| $2.65M | 0.53% |
1,675,000
| – | – |
2024 Q4
1 quarter
|
|
14
Spero Therapeutics
SPRO
$64.6M
| $1.7M | 0.34% |
2,362,348
| – | – |
2024 Q4
1 quarter
|
|
15
Zentalis Pharmaceuticals
ZNTL
$209M
| $1.52M | 0.3% |
953,834
| – | – |
2024 Q4
1 quarter
|
|
16
AN2 Therapeutics
ANTX
$134M
| $973K | 0.19% |
715,295
| – | – |
2024 Q4
1 quarter
|
|
|
17
NextCure
NXTC
$22.8M
| $909K | 0.18% |
157,647
+36,101
| +30% | +$318K |
2024 Q4
1 quarter
|
|
18
Q32 Bio
QTTB
$258M
| $458K | 0.09% |
277,777
| – | – |
2024 Q4
1 quarter
|
|
19
Bolt Biotherapeutics
BOLT
$12.1M
| $250K | 0.05% |
31,305
| – | – |
2024 Q4
1 quarter
|
|
20
Senseonics Holdings Inc
SENS
$397M
| $28.5K | 0.01% |
2,171
| – | – |
2024 Q4
1 quarter
|
|
21
Ginkgo Bioworks
DNA
$673M
| $16.7K | ﹤0.01% |
2,928
| – | – |
2024 Q4
1 quarter
|
|
|
22
DELISTED
Akero Therapeutics
AKRO
| – | – |
-562,626
| Closed | -$15.7M | – |
|
|
23
Haleon
HLN
$45.2B
| – | – |
-197,228,952
| Closed | -$1.88B | – |
|
Similar funds
Pfizer's Q1 2025 Portfolio in Review
As of Q1 2025, Pfizer held 23 positions worth $501M, down 81% from $2.59B the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Pfizer withdrew a net $1.9B in Q1 2025, closing 2 positions. Its most notable exit was Haleon, an estimated $1.88B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Pfizer added an estimated $318K to NextCure.
- Pfizer added most to NextCure in Q1 2025, an estimated $318K increase.
- Pfizer fully exited Haleon in Q1 2025, selling an estimated $1.88B.
- Pfizer's ten largest holdings make up 97% of its $501M portfolio in Q1 2025.
- Pfizer opened 0 new positions and closed 2 in Q1 2025.
- Pfizer's portfolio value fell 81% quarter-over-quarter to $501M.
Based on Pfizer's 13F filing for Q1 2025, filed 13 May 2025.